Tickers

1. Composite Trajectory Verdict

Given SLGN's capital-intensive, acquisitive packaging business with pronounced seasonal working capital swings, all three statements carry roughly equal weight: the income statement reveals margin trajectory, the cash flow statement shows the seasonal funding pattern and free cash flow generation, and the balance sheet captures the leverage and liquidity position that underpin the acquisition strategy.

Composite Trajectory: Mixed

The annual income statement shows top-line growth (+10.7% in 2025) and a modest EBIT margin recovery (9.2% vs 8.8% in 2024), but net income margin has declined for three consecutive years (5.4% → 4.7% → 4.5%). Quarterly results reinforce the margin pressure: Q2 2026 revenue rose 6.8% YoY yet EBIT fell 9.9% and net income fell 14.8%, with gross margin compressing 150 bps. Annual operating cash flow has stabilized near $730M after a jump from 2023, but first-half 2026 operating cash flow deteriorated to -$994M from -$905M, requiring heavier revolver borrowings ($1.08B outstanding at June 30, 2026 vs $0 at Dec. 31, 2025). The balance sheet shows equity growing ($2.38B at June 2026 vs $2.27B at Dec. 2025) but total debt principal rising to $4.85B from $4.36B, with a concentrated maturity wall ($1.4B in 2028, $1.9B thereafter). Improving dimensions: revenue growth, annual operating cash flow stability, equity accumulation. Deteriorating dimensions: net income margin trend, quarterly profitability, seasonal cash flow draw, and gross leverage.

2. Red Flags

• Recurring rationalization charges – $59.5M (2024), $60.5M (2025), $20.8M (H1 2025), $27.2M (H1 2026) despite a stated two-year $50M savings program (10-K MD&A, 10-Q 2026-06-30 MD&A).
• Declining net income margin – 5.4% (2023) → 4.7% (2024) → 4.5% (2025) (10-K Consolidated Statements of Operations); Q2 2026 4.6% vs 5.8% (2025), YTD 2026 4.3% vs 5.3% (10-Q 2026-06-30 Condensed Statements of Operations).
• Gross margin compression in 2026 – Q2 2026 17.9% vs 19.4% (2025); YTD 2026 17.5% vs 18.9% (2025), attributed partly to pass-through math and mix (10-Q 2026-06-30 MD&A).
• Rising interest expense – $189.4M (2025) vs $167.4M (2024) due to Weener Packaging acquisition debt (10-K MD&A).
• Effective tax rate spike – 30.2% (2025) vs 20.7% (2024) from non-deductible rationalization costs (10-K MD&A).
• Seasonal working capital funding via revolver – H1 2026 operating cash flow -$993.9M financed by $1.1B net revolver borrowings; revolver outstanding $1.08B at June 30, 2026 with only $402.4M available (10-Q 2026-06-30 Cash Flow, MD&A).
• Concentrated debt maturities – $627.9M (2026), $194.3M (2027), $1.4B (2028), $1.9B (thereafter) (10-K Contractual Obligations).
• Supplier SCF dependency – $438.5M (Dec. 2025) and $370.4M (June 2026) of payables in SCF program; termination would increase working capital needs (10-K MD&A, 10-Q 2026-06-30 Note 9).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual revenue grew 10.7% to $6.48B in 2025 (vs $5.85B in 2024) driven by Weener Packaging inclusion, pass-through pricing, and volume gains in metal containers (10-K Consolidated Statements of Operations). Consolidated EBIT margin improved to 9.2% from 8.8% but remains below the 9.9% posted in 2023 (10-K MD&A). Net income margin has contracted each year: 5.4% (2023) → 4.7% (2024) → 4.5% (2025) (10-K Consolidated Statements of Operations). Quarterly trends confirm margin pressure: Q2 2026 revenue rose 6.8% YoY to $1.64B, yet EBIT fell 9.9% to $151.0M (9.2% margin vs 10.9%) and net income fell 14.8% to $75.8M (4.6% vs 5.8%) (10-Q 2026-06-30 Condensed Statements of Operations, MD&A). YTD 2026 EBIT declined 6.9% to $277.6M (8.7% margin vs 9.9%) with net income down 11.5% to $138.8M (4.3% vs 5.3%) (10-Q 2026-06-30). Gross margin compressed 140-150 bps in both Q1 and Q2 2026 versus 2025 (10-Q 2026-06-30 MD&A; 10-Q 2026-03-31 MD&A). Segment adjusted EBIT margins (non-GAAP) also declined in dispensing (15.1% vs 15.4% Q2) and metal (8.6% vs 10.5% Q2), while custom improved (16.4% vs 15.5% Q2) (10-Q 2026-06-30 MD&A).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Stable

Annual operating cash flow plateaued at $729.8M in 2025 versus $721.9M in 2024, up substantially from $482.6M in 2023 (10-K Consolidated Statements of Cash Flows). Capital expenditures rose to $307.1M (2025) from $262.8M (2024) and $226.8M (2023), yielding free cash flow (operating less capex) of roughly $423M in 2025 vs $459M in 2024 and $256M in 2023 (10-K Consolidated Statements of Cash Flows). The first half of each year is seasonally negative: H1 2026 operating cash flow was -$993.9M vs -$904.9M in H1 2025, funded by net revolver borrowings of $1.1B and $1.4B respectively (10-Q 2026-06-30 Condensed Statements of Cash Flows). At June 30, 2026, revolving loans outstanding reached $1.08B with $402.4M remaining availability, compared to zero revolver balance at Dec. 31, 2025 (10-Q 2026-06-30 Note 6, MD&A). Dividends paid increased modestly to $85.8M (2025) from $82.1M (2024) (10-K MD&A). Share repurchases accelerated to $74.9M (2025) from $9.3M (2024) (10-K MD&A).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets grew to $9.60B at June 30, 2026 from $9.40B at Dec. 31, 2025 (10-Q 2026-06-30 Balance Sheet; 10-K Balance Sheet). Total debt principal increased to $4.85B at June 30, 2026 from $4.36B at Dec. 31, 2025, primarily due to seasonal revolver borrowings ($1.08B outstanding at June 30, 2026 vs $0 at Dec. 31, 2025) (10-Q 2026-06-30 Note 6; 10-K MD&A). Non-current long-term debt declined slightly to $3.66B from $3.72B (10-Q 2026-06-30 Balance Sheet; 10-K Balance Sheet). Cash fell to $351.5M from $1.08B, reflecting seasonal working capital build (receivables $1.45B vs $589.4M; inventories $1.23B vs $1.08B) and debt repayments including the $500M 1.4% Notes (10-Q 2026-06-30 Balance Sheet, Cash Flow; 10-Q 2026-06-30 MD&A). Stockholders' equity rose to $2.38B from $2.27B on retained earnings (10-Q 2026-06-30 Balance Sheet; 10-K Balance Sheet). Contractual obligations show $627.9M due in 2026, $194.3M in 2027, and $1.4B in 2028 (10-K Contractual Obligations). The company remains in compliance with all financial covenants (10-Q 2026-06-30 MD&A).

6. Data Gaps

• Quarterly results for Q3 and Q4 2025 (only annual 2025 and Q1/Q2 2025/2026 provided)
• Q3 2026 and full-year 2026 results (not yet filed)
• Segment-level cash flows (not disclosed)
• Reported EBITDA (only depreciation & amortization provided; EBITDA must be approximated)
• Covenant net leverage ratio (referenced but not quantified in filings)
• Standalone Q2 2026 cash flow (only YTD provided; Q2 alone not separable without Q1 cash flow statement)